Q2 2015 13F Holders as of 6/30/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
157
-
Total 13F shares, excl. options
-
94.7M
-
Shares change
-
+3.11M
-
Total reported value, excl. options
-
$2.14B
-
Value change
-
+$79.2M
-
Put/Call ratio
-
0.53
-
Number of buys
-
81
-
Number of sells
-
-63
-
Price
-
$22.58
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2015
181 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q2 2015.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 157 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94.7M shares
of 124M outstanding shares and own 76.56% of the company stock.
Largest 10 shareholders include Third Security, LLC (19.8M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (9.66M shares), VANGUARD GROUP INC (6.86M shares), BB BIOTECH AG (6.08M shares), MILLENNIUM MANAGEMENT LLC (5.5M shares), FMR LLC (4.32M shares), BlackRock Fund Advisors (4.2M shares), First Eagle Investment Management, LLC (4.16M shares), Sectoral Asset Management Inc (3.48M shares), and STATE STREET CORP (2.99M shares).
This table shows the top 157 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.